Overall, these results identify Tregs as key regulators of immune escape of LSCs and TNFRSF4 as a potential target to reduce the function of Tregs and boost antileukemic immunity in CML. The gene discussed is TNFRSF4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.